Is MIST or HELP more profitable?

Cybin's return on equity of -68.27% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Milestone Pharmaceuticals N/A -339.33% -61.79% Cybin N/A -68.27% -58.26%

Does the media favor MIST or HELP?

In the previous week, Cybin had 2 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 5 mentions for Cybin and 3 mentions for Milestone Pharmaceuticals. Cybin's average media sentiment score of 0.40 beat Milestone Pharmaceuticals' score of 0.00 indicating that Cybin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cybin 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TLRY or MIST?

In the previous week, Tilray Brands had 19 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 22 mentions for Tilray Brands and 3 mentions for Milestone Pharmaceuticals. Tilray Brands' average media sentiment score of 0.92 beat Milestone Pharmaceuticals' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 11 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Milestone Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SPRY or MIST?

In the previous week, ARS Pharmaceuticals had 16 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 3 mentions for Milestone Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.16 beat Milestone Pharmaceuticals' score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 16 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Milestone Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AQST or MIST?

In the previous week, Milestone Pharmaceuticals had 1 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 3 mentions for Milestone Pharmaceuticals and 2 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.00 equaled Milestone Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Milestone Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor OVID or MIST?

In the previous week, Ovid Therapeutics had 2 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 5 mentions for Ovid Therapeutics and 3 mentions for Milestone Pharmaceuticals. Ovid Therapeutics' average media sentiment score of 0.63 beat Milestone Pharmaceuticals' score of 0.00 indicating that Ovid Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ovid Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Milestone Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Milestone Pharmaceuticals (MIST) Competitors

$1.22 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$1.24 +0.02 (+1.56%)

As of 04:20 AM Eastern

Compare

MIST vs. HELP, TLRY, SPRY, AQST, and OVID

Should you buy Milestone Pharmaceuticals stock or one of its competitors? MarketBeat compares Milestone Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Milestone Pharmaceuticals include Cybin (HELP), Tilray Brands (TLRY), ARS Pharmaceuticals (SPRY), Aquestive Therapeutics (AQST), and Ovid Therapeutics (OVID). These companies are all part of the "pharmaceuticals" industry.

How does Milestone Pharmaceuticals compare to Cybin?

Milestone Pharmaceuticals (NASDAQ:MIST) and Cybin (NASDAQ:HELP) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Milestone Pharmaceuticals presently has a consensus target price of $7.25, indicating a potential upside of 494.26%. Cybin has a consensus target price of $45.25, indicating a potential upside of 289.75%. Given Milestone Pharmaceuticals' higher possible upside, equities analysts clearly believe Milestone Pharmaceuticals is more favorable than Cybin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cybin's return on equity of -68.27% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%
Cybin	N/A	-68.27%	-58.26%

In the previous week, Cybin had 2 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 5 mentions for Cybin and 3 mentions for Milestone Pharmaceuticals. Cybin's average media sentiment score of 0.40 beat Milestone Pharmaceuticals' score of 0.00 indicating that Cybin is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cybin	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Milestone Pharmaceuticals has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	97.99	-$63.06M	-$0.68	N/A
Cybin	N/A	N/A	-$148M	-$4.23	N/A

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 15.0% of Cybin shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Milestone Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Cybin has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Summary

Milestone Pharmaceuticals beats Cybin on 8 of the 15 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

9.4% of Tilray Brands shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 0.8% of Tilray Brands shares are owned by company insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Milestone Pharmaceuticals has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$915.45M	0.68	-$121.40M	-$1.08	N/A
Milestone Pharmaceuticals	$1.55M	97.99	-$63.06M	-$0.68	N/A

Milestone Pharmaceuticals has a net margin of 0.00% compared to Tilray Brands' net margin of -13.11%. Tilray Brands' return on equity of -7.76% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-13.11%	-7.76%	-5.59%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

In the previous week, Tilray Brands had 19 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 22 mentions for Tilray Brands and 3 mentions for Milestone Pharmaceuticals. Tilray Brands' average media sentiment score of 0.92 beat Milestone Pharmaceuticals' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	11 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Milestone Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tilray Brands presently has a consensus price target of $11.00, indicating a potential upside of 140.70%. Milestone Pharmaceuticals has a consensus price target of $7.25, indicating a potential upside of 494.26%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Tilray Brands has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

Summary

Milestone Pharmaceuticals beats Tilray Brands on 9 of the 15 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to ARS Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ARS Pharmaceuticals currently has a consensus target price of $28.20, indicating a potential upside of 357.79%. Milestone Pharmaceuticals has a consensus target price of $7.25, indicating a potential upside of 494.26%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than ARS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, ARS Pharmaceuticals had 16 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 3 mentions for Milestone Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.16 beat Milestone Pharmaceuticals' score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	16 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Milestone Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Milestone Pharmaceuticals has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. ARS Pharmaceuticals' return on equity of -153.61% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

Milestone Pharmaceuticals has lower revenue, but higher earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$98.99M	6.18	-$171.30M	-$2.01	N/A
Milestone Pharmaceuticals	$1.55M	97.99	-$63.06M	-$0.68	N/A

ARS Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

Summary

Milestone Pharmaceuticals beats ARS Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Aquestive Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Aquestive Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 115.74%. Milestone Pharmaceuticals has a consensus price target of $7.25, indicating a potential upside of 494.26%. Given Milestone Pharmaceuticals' higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Aquestive Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

In the previous week, Milestone Pharmaceuticals had 1 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 3 mentions for Milestone Pharmaceuticals and 2 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.00 equaled Milestone Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Milestone Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Milestone Pharmaceuticals has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

Milestone Pharmaceuticals has lower revenue, but higher earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.10	-$83.78M	-$0.61	N/A
Milestone Pharmaceuticals	$1.55M	97.99	-$63.06M	-$0.68	N/A

32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by company insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Aquestive Therapeutics beats Milestone Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Ovid Therapeutics?

Ovid Therapeutics (NASDAQ:OVID) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Ovid Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

In the previous week, Ovid Therapeutics had 2 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 5 mentions for Ovid Therapeutics and 3 mentions for Milestone Pharmaceuticals. Ovid Therapeutics' average media sentiment score of 0.63 beat Milestone Pharmaceuticals' score of 0.00 indicating that Ovid Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Milestone Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Milestone Pharmaceuticals has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -22.51% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-22.51%	-18.67%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

Ovid Therapeutics has higher revenue and earnings than Milestone Pharmaceuticals. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	67.71	-$17.41M	-$0.29	N/A
Milestone Pharmaceuticals	$1.55M	97.99	-$63.06M	-$0.68	N/A

Ovid Therapeutics presently has a consensus target price of $5.71, indicating a potential upside of 117.27%. Milestone Pharmaceuticals has a consensus target price of $7.25, indicating a potential upside of 494.26%. Given Milestone Pharmaceuticals' higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Ovid Therapeutics beats Milestone Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Milestone Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIST vs. The Competition

Export

Metric	Milestone Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$151.89M	$11.85B	$7.00B	$12.99B
Dividend Yield	N/A	2.70%	2.58%	10.20%
P/E Ratio	-1.79	790.97	270.59	25.05
Price / Sales	97.99	743.50	598.01	84.12
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	3.13	10.38	11.38	6.43
Net Income	-$63.06M	$2.78B	$3.45B	$348.10M
7 Day Performance	8.93%	2.85%	3.46%	2.68%
1 Month Performance	-4.69%	-0.56%	-0.66%	-0.83%
1 Year Performance	-18.67%	192.62%	77.38%	23.97%

Milestone Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIST Milestone Pharmaceuticals	1.4072 of 5 stars	$1.22 flat	$7.25 +494.3%	-18.7%	$151.89M	$1.55M	N/A	30	Positive News Upcoming Earnings
HELP Cybin	2.523 of 5 stars	$8.06 +3.1%	$45.25 +461.4%	N/A	$546.41M	N/A	N/A	50	Gap Down
TLRY Tilray Brands	4.3286 of 5 stars	$4.64 +2.2%	$11.00 +137.1%	-29.6%	$529.13M	$915.45M	N/A	2,842
SPRY ARS Pharmaceuticals	2.6392 of 5 stars	$5.46 +6.4%	$28.20 +416.5%	-64.8%	$509.42M	$98.99M	N/A	90	Trending News Upcoming Earnings Gap Down
AQST Aquestive Therapeutics	1.5934 of 5 stars	$3.79 +2.7%	$8.50 +124.3%	+1.0%	$463.60M	$44.54M	N/A	160	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIST) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Milestone Pharmaceuticals (MIST) Competitors

MIST vs. HELP, TLRY, SPRY, AQST, and OVID

How does Milestone Pharmaceuticals compare to Cybin?

Summary

How does Milestone Pharmaceuticals compare to Tilray Brands?

Summary

How does Milestone Pharmaceuticals compare to ARS Pharmaceuticals?

Summary

How does Milestone Pharmaceuticals compare to Aquestive Therapeutics?

Summary

How does Milestone Pharmaceuticals compare to Ovid Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIST vs. The Competition

Milestone Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Milestone Pharmaceuticals (MIST) Competitors

MIST vs. HELP, TLRY, SPRY, AQST, and OVID

How does Milestone Pharmaceuticals compare to Cybin?

Do analysts prefer MIST or HELP?

Is MIST or HELP more profitable?

Does the media favor MIST or HELP?

Which has higher valuation and earnings, MIST or HELP?

Do institutionals and insiders believe in MIST or HELP?

Which has more risk and volatility, MIST or HELP?

Summary

How does Milestone Pharmaceuticals compare to Tilray Brands?

Do insiders and institutionals have more ownership in TLRY or MIST?

Which has stronger valuation and earnings, TLRY or MIST?

Is TLRY or MIST more profitable?

Does the media refer more to TLRY or MIST?

Do analysts recommend TLRY or MIST?

Which has more volatility & risk, TLRY or MIST?

Summary

How does Milestone Pharmaceuticals compare to ARS Pharmaceuticals?

Do insiders & institutionals have more ownership in SPRY or MIST?

Do analysts recommend SPRY or MIST?

Does the media refer more to SPRY or MIST?

Is SPRY or MIST more profitable?

Which has better earnings & valuation, SPRY or MIST?

Which has more risk and volatility, SPRY or MIST?

Summary

How does Milestone Pharmaceuticals compare to Aquestive Therapeutics?

Do analysts recommend AQST or MIST?

Which has more risk & volatility, AQST or MIST?

Does the media favor AQST or MIST?

Is AQST or MIST more profitable?

Which has stronger earnings & valuation, AQST or MIST?

Do insiders and institutionals believe in AQST or MIST?

Summary

How does Milestone Pharmaceuticals compare to Ovid Therapeutics?

Do institutionals & insiders believe in OVID or MIST?

Which has more risk and volatility, OVID or MIST?

Does the media favor OVID or MIST?

Is OVID or MIST more profitable?

Which has better valuation & earnings, OVID or MIST?

Do analysts recommend OVID or MIST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIST vs. The Competition

Milestone Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools